Who we are and what we do

  • A public unlisted Australian life sciences company
  • We discover, develop and commercialise novel anticancer and wound healing pharmaceuticals for human and veterinary markets.
  • Our lead drug, tigilanol tiglate, is a small molecule anticancer pharmaceutical targeting a range of solid tumours across multiple species.
  • The simultaneous development of products for both the vet and human markets enables validation of technology and reduces risks for human development, while generating early revenues.

Our Board of Directors

Rick Holliday-SmithRick Holliday-Smith
Non-executive Chairman
Dr Victoria Gordon​Dr Victoria Gordon​
Managing Director & Chief Executive Officer
Dr Paul ReddellDr Paul Reddell
Executive Director and Chief Scientific Officer
Mr Nicholas MooreMr Nicholas Moore
Non-executive Director
Dr Susan FodenDr Susan Foden
Non-executive Director
Mr Andrew DenverMr Andrew Denver
Non-executive Director
Professor Bruce Robinson ACProfessor Bruce Robinson AC
Non-executive Director
Associate Professor Steven OgbourneAssociate Professor Steven Ogbourne
Non-executive Director
Mr Neville MitchellMr Neville Mitchell
Non-executive Director
Mr Hamish CorlettMr Hamish Corlett
Non-executive Director